Standardized treatment of acute leukemia by haplo-identical stem cell transplantation

doi:10.3969/j.issn.1004-583X.2021.10.001

Abstract

Abstract:

Haplo-identical stem cell transplantation(Haplo-SCT) is one of the most rapidly developing subjects in the field of transplantation in recent years. Haplo-SCT is mainly applied in more experienced centers due to the complexity of its technics. In this review, the history and current status of Haplo-SCT in treating leukemias are summarized, and the indications, donor selection, and relapse prevention/management in the “Beijing Protocol” Haplo-SCT as well as transplant strategies in special populations including elderly people are emphatically described, with the aim of providing the basis for further standardized promotion of Haplo-SCT in domestic centers.

Key words: transplantation,haploidentical, leukemia,acute

CLC Number:

R733.7

Ma Rui, Sun Yuqian. Standardized treatment of acute leukemia by haplo-identical stem cell transplantation[J]. Clinical Focus, 2021, 36(10): 869-873.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.10.001

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I10/869

References 39

[1]	Sun YQ, Chang YJ, Huang XJ. Update on current research into haploidentical hematopoietic stem cell transplantation[J]. Expert Rev Hematol, 2018,3(6):1-12. doi: 10.1586/ehm.09.69 URL
[2]	Zhang XH, Chen J, Han MZ, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation:2021 update[J]. J Hematol Oncol, 2021,14(1):145. doi: 10.1186/s13045-021-01159-2 URL
[3]	Xu LP, Lu PH, Wu DP, et al. Hematopoietic stem cell transplantation activity in China 2019:A report from the Chinese blood and marrow transplantation registry group[J]. Bone Marrow Transplant, 2021:1-8.
[4]	Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation[J]. Blood. 2006,107(8):3065-3073. doi: 10.1182/blood-2005-05-2146 URL
[5]	Wang Y, Liu QF, Xu LP, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study[J]. Blood, 2015,125(25):3956-3962. doi: 10.1182/blood-2015-02-627786 pmid: 25940714
[6]	Wang Y, Liu Q, Xu LP, et al. Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study[J]. Clin Cancer Res, 2016,22(14):3467-3476. doi: 10.1158/1078-0432.CCR-15-2335 pmid: 26927664
[7]	Wang Y, Wang HX, Lai YR, et al. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant[J]. Leukemia. 2016,30(10):2055-2063. doi: 10.1038/leu.2016.110 pmid: 27133816
[8]	Sun YQ, Beohou E, Labopin M, et al. Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database[J]. Haematologica, 2016,101(8):e352-e354. doi: 10.3324/haematol.2015.140509 URL
[9]	Duarte RF, Labopin M, Bader P, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019[J]. Bone Marrow Transplant, 2019,54(10):1525-1552. doi: 10.1038/s41409-019-0516-2 URL
[10]	Kanate AS, Majhail NS, Savani BN, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: Guidelines from the American society for transplantation and cellular therapy[J]. Biol Blood Marrow Transplant, 2020,26(7):1247-1256. doi: 10.1016/j.bbmt.2020.03.002 URL
[11]	Huang XJ, Zhu HH, Chang YJ, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission[J]. Blood, 2012,119(23):5584-5590. doi: 10.1182/blood-2011-11-389809 URL
[12]	Lv M, Wang Y, Chang YJ, et al. Myeloablative haploidentical transplantation is superior to chemotherapy for patients with intermediate-risk acute myelogenous leukemia in first complete remission[J]. Clin Cancer Res, 2019,25(6):1737-1748. doi: 10.1158/1078-0432.CCR-18-1637 URL
[13]	Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial[J]. Blood, 2013,121(20):4056-4062. doi: 10.1182/blood-2012-11-468348 URL
[14]	Duan W, Liu X, Jia J, et al. The loss or absence of minimal residual disease of<0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis[J]. Br J Haematol, 2021,192(2):265-271. doi: 10.1111/bjh.v192.2 URL
[15]	Deng DX, Zhu HH, Liu YR, et al. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations[J]. Leuk Lymphoma, 2019,60(9):2181-2189. doi: 10.1080/10428194.2019.1576868 URL
[16]	Lv M, Jiang Q, Zhou DB, et al. Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1[J]. J Hematol Oncol, 2020,13(1):52. doi: 10.1186/s13045-020-00879-1 URL
[17]	Guo H, Chang YJ, Hong Y, et al. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation[J]. Cell Mol Immunol, 2021,18(5):1172-1185. doi: 10.1038/s41423-020-00597-1 URL
[18]	Chang YJ, Wang Y, Liu YR, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis[J]. J Hematol Oncol, 2017,10(1):134. doi: 10.1186/s13045-017-0502-3 URL
[19]	Chang YJ, Wang Y, Xu LP, et al. Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: A phase 3 genetically randomized study[J]. J Hematol Oncol, 2020,13(1):27. doi: 10.1186/s13045-020-00860-y URL
[20]	Wang Y, Liu QF, Wu DP, et al. Improved survival after offspring donor transplant compared with older aged‐matched siblings for older leukaemia patients[J]. Br J Haematol, 2020,189(1):153-161. doi: 10.1111/bjh.v189.1 URL
[21]	Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA- haplotype-mismatched transplant?[J]. Blood, 2014,124(6):843-850. doi: 10.1182/blood-2014-03-563130 pmid: 24916508
[22]	Yan CH, Xu LP, Wang FR, et al. Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2016,51(3):391-397. doi: 10.1038/bmt.2015.306 URL
[23]	Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia[J]. Curr Treat Options Oncol, 2017,18(3):17. doi: 10.1007/s11864-017-0456-2 URL
[24]	Thol F, Schlenk RF, Heuser M, et al. How I treat refractory and early relapsed acute myeloid leukemia[J]. Blood, 2015,126(3):319-327.
[25]	Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med, 2013,368(16):1509-1518. doi: 10.1056/NEJMoa1215134 URL
[26]	Weisdorf DJ, Millard HR, Horowitz MM, et al. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission[J]. Cancer, 2017,123(11):2025-2034. doi: 10.1002/cncr.30536 pmid: 28117884
[27]	Wu Q, Zhang R, Wang H, et al. Comparison of outcomes of idarubicin intensified TBI-CY and traditional TBI-CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A single center experience[J]. Leuk Res, 2015,39(11):1192-1200. doi: 10.1016/j.leukres.2015.08.015 URL
[28]	Liu QF, Fan ZP, Zhang Y, et al. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-Host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia[J]. Biol Blood Marrow Transplant, 2009,15(11):1376-1385. doi: 10.1016/j.bbmt.2009.06.017 URL
[29]	Zhao XS, Yan CH, Liu DH, et al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity[J]. Ann Hematol, 2013,92(8):1111-1119. doi: 10.1007/s00277-013-1733-1 URL
[30]	Yan CH, Liu DH, Liu KY, et al. Risk stratification directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation[J]. Blood, 2012,119(14):3256-3262. doi: 10.1182/blood-2011-09-380386 URL
[31]	Mo XD, Zhang XH, Xu LP, et al. Interferon-alpha: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2015,21(11):1939-1947. doi: 10.1016/j.bbmt.2015.06.014 URL
[32]	Chen H, Liu KY, Xu LP, et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia[J]. J Hematol Oncol, 2012,5:29. doi: 10.1186/1756-8722-5-29 URL
[33]	Antar A, Kharfan-Dabaja MA, Mahfouz R, et al. Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation[J]. Clin Lymphoma Myeloma Leuk, 2015,15(5):298-302. doi: 10.1016/j.clml.2014.12.005 URL
[34]	Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation[J]. Br J Haematol, 2017,179(4):598-605. doi: 10.1111/bjh.2017.179.issue-4 URL
[35]	Ganguly S, Amin M, Divine C, et al. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)[J]. Ann Hematol, 2013,92(4):549-550. doi: 10.1007/s00277-012-1607-y URL
[36]	Chen H, Liu KY, Xu LP, et al. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Chin Med J (Engl), 2011,124(2):246-252.
[37]	Chen YB, Li S, Lane AA, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia[J]. Biol Blood Marrow Transplant, 2014,20(12):2042-2048. doi: 10.1016/j.bbmt.2014.09.007 URL
[38]	Lima D, Marcos, Silva DP, et al. Maintenance therapy with low-dose azacitidine (AZA) after allogeneic hematopoietic stem cell transplantation(HSCT) for relapsed or refractory AML or MDS: A dose and schedule finding study[J]. Blood, 2008,112(11):414. doi: 10.1182/blood.V112.11.414.414 URL
[39]	Sun YQ, Han TT, Wang Y, et al. Haploidentical stem cell transplantation with a novel conditioning regimen in older patients: A prospective single-arm phase 2 study[J]. Front Oncol, 2021,11:639502. doi: 10.3389/fonc.2021.639502 URL